Shelton Capital Management boosted its stake in shares of AbbVie Inc. (NYSE:ABBV) by 1.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 107,388 shares of the company’s stock after buying an additional 1,457 shares during the quarter. Shelton Capital Management’s holdings in AbbVie were worth $6,997,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently modified their holdings of the company. Verde Servicos Internacionais S.A. grew its position in shares of AbbVie by 2.0% in the first quarter. Verde Servicos Internacionais S.A. now owns 39,840 shares of the company’s stock valued at $2,595,000 after purchasing an additional 798 shares during the last quarter. Gierl Augustine Investment Management Inc grew its position in shares of AbbVie by 8.0% in the first quarter. Gierl Augustine Investment Management Inc now owns 54,762 shares of the company’s stock valued at $3,568,000 after purchasing an additional 4,058 shares during the last quarter. Weybosset Research & Management LLC grew its position in shares of AbbVie by 21.6% in the first quarter. Weybosset Research & Management LLC now owns 4,500 shares of the company’s stock valued at $293,000 after purchasing an additional 800 shares during the last quarter. Stokes & Hubbell Capital Management LLC grew its position in shares of AbbVie by 23.8% in the first quarter. Stokes & Hubbell Capital Management LLC now owns 44,284 shares of the company’s stock valued at $2,886,000 after purchasing an additional 8,503 shares during the last quarter. Finally, Prospera Financial Services Inc grew its position in shares of AbbVie by 305.4% in the first quarter. Prospera Financial Services Inc now owns 67,777 shares of the company’s stock valued at $4,409,000 after purchasing an additional 51,057 shares during the last quarter. Institutional investors own 68.29% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece of content was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another website, it was illegally stolen and reposted in violation of United States & international copyright law. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2017/09/11/abbvie-inc-abbv-holdings-lifted-by-shelton-capital-management.html.

Shares of AbbVie Inc. (ABBV) traded up 0.627% during trading on Monday, hitting $85.875. 5,095,357 shares of the company traded hands. The stock has a market cap of $136.89 billion, a price-to-earnings ratio of 21.120 and a beta of 1.48. The firm has a 50 day moving average price of $72.68 and a 200-day moving average price of $68.61. AbbVie Inc. has a one year low of $55.06 and a one year high of $86.09.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Friday, July 28th. The company reported $1.42 earnings per share for the quarter, beating analysts’ consensus estimates of $1.40 by $0.02. The business had revenue of $6.94 billion for the quarter, compared to the consensus estimate of $6.93 billion. AbbVie had a net margin of 24.77% and a return on equity of 150.27%. AbbVie’s revenue for the quarter was up 7.6% on a year-over-year basis. During the same period last year, the company posted $1.26 EPS. Analysts predict that AbbVie Inc. will post $5.52 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Wednesday, November 15th. Investors of record on Friday, October 13th will be given a $0.64 dividend. The ex-dividend date of this dividend is Thursday, October 12th. This represents a $2.56 dividend on an annualized basis and a dividend yield of 3.00%. AbbVie’s dividend payout ratio is 62.90%.

In related news, Chairman Richard A. Gonzalez sold 193,131 shares of the stock in a transaction that occurred on Monday, August 7th. The shares were sold at an average price of $71.00, for a total value of $13,712,301.00. Following the sale, the chairman now directly owns 469,623 shares in the company, valued at approximately $33,343,233. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Carlos Alban sold 45,800 shares of the stock in a transaction that occurred on Wednesday, June 14th. The shares were sold at an average price of $70.00, for a total transaction of $3,206,000.00. Following the completion of the sale, the executive vice president now owns 160,545 shares in the company, valued at $11,238,150. The disclosure for this sale can be found here. Insiders sold a total of 490,491 shares of company stock worth $34,684,639 over the last quarter. 0.23% of the stock is currently owned by corporate insiders.

Several analysts have recently commented on the stock. Piper Jaffray Companies reiterated a “buy” rating and issued a $85.00 price target on shares of AbbVie in a research report on Thursday, August 3rd. Cowen and Company reiterated a “hold” rating and issued a $95.00 price target (up from $70.00) on shares of AbbVie in a research report on Monday. BidaskClub lowered shares of AbbVie from a “buy” rating to a “hold” rating in a research report on Friday, August 4th. Jefferies Group LLC reiterated a “buy” rating and issued a $94.00 price target on shares of AbbVie in a research report on Friday. Finally, Vetr upgraded shares of AbbVie from a “hold” rating to a “buy” rating and set a $76.28 price target on the stock in a research report on Wednesday, July 26th. Seven research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. AbbVie has an average rating of “Buy” and a consensus target price of $79.25.

AbbVie Company Profile

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Stock Ratings for AbbVie Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. and related stocks with our FREE daily email newsletter.